April 7, 2020
Biophytis Announces Launch of a Public Offering of Share Subscription Warrants (BSA) with an Irreducible Priority Subscription Period for Existing Shareholders. Read the Press Release
April 7, 2020
Biophytis has signed a New Convertible Bond Financing of €24 million from Atlas to Continue the Development of Sarconeos (BIO101). Read the Press Release
April 6, 2020
2019 Annual Financial Report made available. Read the Press Release
March 30, 2020
Biophytis Receives Approval from the Belgian Regulatory Agency to Proceed with the MYODA Program for Clinical Development of Sarconeos (BIO101) in Patients with DMD. Read the Press Release
March 24, 2020
Biophytis Completes Recruitment of SARA-INT Phase 2b Study, Evaluating the Efficacy of Sarconeos (BIO101) in the Treatment of Sarcopenia. Read the Press Release
March 17, 2020
Biophytis Reports 2019 Full Year Results and Provides Operational Update. Read the Press Release
March 3, 2020
Biophytis to Present the Preliminary Results of SARA-OBS and its Impact on SARA-INT, the Phase 2b clinical study, at the 10th International Conference on Frailty and Sarcopenia Research (ICFSR 2020) in Toulouse, France. Read the Press Release
February 14, 2020
Biophytis Trading will resume on February 14th, 2020 at 09:00 CET. Read the Press Release
February 14, 2020
Biophytis successfully completes a € 3.3 million capital increase to strengthen its financing structure. Read the Press Release
13 février 2020
Biophytis shares trading is suspended pending a new press release. Read the Press Release